TC BioPharm (Holdings) PLC (TCBP)
0.6488
-0.27
(-29.57%)
USD |
NASDAQ |
Nov 14, 16:00
0.71
+0.06
(+9.43%)
After-Hours: 20:00
TC BioPharm Research and Development Expense (Quarterly): 1.648M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 1.648M |
| June 30, 2023 | 2.683M |
| March 31, 2023 | 2.351M |
| Date | Value |
|---|---|
| December 31, 2021 | 2.218M |
| September 30, 2021 | 2.211M |
| December 31, 2020 | 2.068M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.648M
Minimum
Mar 2024
2.683M
Maximum
Jun 2023
2.196M
Average
2.215M
Median
Research and Development Expense (Quarterly) Benchmarks
| Adaptimmune Therapeutics PLC | 40.45M |
| Biodexa Pharmaceuticals PLC | -- |
| Verona Pharma PLC | 10.55M |
| NuCana PLC | 8.540M |
| Autolus Therapeutics PLC | 36.61M |